drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous T lymphocytes genetically engineered via lentiviral transduction to express a B7-H3–targeted chimeric antigen receptor incorporating an IL-7Rα intracellular signaling domain to enhance persistence and proliferation; administered intraventricularly via CNS catheter.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting B7-H3 (CD276). CAR engagement of B7-H3 on tumor cells triggers MHC-independent T-cell activation via CD3ζ signaling, inducing cytotoxic killing and cytokine release. An incorporated IL-7 receptor alpha intracellular signaling domain augments IL-7/JAK-STAT5 survival and proliferative signals to enhance CAR T-cell persistence and expansion, supporting activity in the CNS when delivered intraventricularly.
drug_name
Autologous B7-H3 (CD276)-specific CAR T cells with IL-7 receptor alpha signaling domain
nct_id_drug_ref
NCT06221553